• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病的综合治疗方法。

An integrated approach to the medical treatment of chronic obstructive pulmonary disease.

机构信息

Asthma and COPD Program, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

出版信息

Med Clin North Am. 2012 Jul;96(4):811-26. doi: 10.1016/j.mcna.2012.05.002.

DOI:10.1016/j.mcna.2012.05.002
PMID:22793946
Abstract

COPD is a treatable condition for which careful and objective evaluation of patients’ lung function, symptoms, exercise capacity, and exacerbation history on an ongoing basis is essential so that treatments may be individualized as much as possible. Although the comparative effectiveness of drug classes has not yet been tested completely in COPD, virtually all inhaled COPD therapies improve lung function, quality of life, and reduce COPD exacerbations, which fulfills the major goals of care. Pulmonary rehabilitation is safe, effective, and a crucial component of COPD therapy. Newer therapies have been developed with the specific purpose of reducing COPD exacerbations and should be prescribed to individuals who have evidence of recurrent exacerbations despite maximal inhaled maintenance medications.

摘要

COPD 是一种可治疗的疾病,需要持续仔细和客观地评估患者的肺功能、症状、运动能力和加重病史,以便尽可能对治疗进行个体化。虽然药物类别的比较效果尚未在 COPD 中完全测试,但几乎所有吸入性 COPD 治疗都能改善肺功能、生活质量并减少 COPD 加重,这满足了护理的主要目标。肺康复是安全有效的,是 COPD 治疗的重要组成部分。新的治疗方法是为减少 COPD 加重而专门开发的,应该开给那些尽管使用了最大吸入维持药物但仍有反复加重证据的患者。

相似文献

1
An integrated approach to the medical treatment of chronic obstructive pulmonary disease.慢性阻塞性肺疾病的综合治疗方法。
Med Clin North Am. 2012 Jul;96(4):811-26. doi: 10.1016/j.mcna.2012.05.002.
2
Common lung conditions: chronic obstructive pulmonary disease.常见肺部疾病:慢性阻塞性肺疾病
FP Essent. 2013 Jun;409:23-31.
3
[Clinical profile of roflumilast].[罗氟司特的临床概况]
Arch Bronconeumol. 2010 Dec;46 Suppl 10:25-32. doi: 10.1016/S0300-2896(10)70053-3.
4
Innovations to achieve excellence in COPD diagnosis and treatment in primary care.在初级保健中实现 COPD 诊断和治疗卓越的创新。
Postgrad Med. 2010 Sep;122(5):150-64. doi: 10.3810/pgm.2010.09.2212.
5
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.慢性阻塞性肺疾病稳定期的诊断与管理:美国医师学会、美国胸科学会、美国胸科学会和欧洲呼吸学会的临床实践指南更新。
Ann Intern Med. 2011 Aug 2;155(3):179-91. doi: 10.7326/0003-4819-155-3-201108020-00008.
6
The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding.以患者为中心的结局在慢性阻塞性肺疾病病程中的作用:长期研究如何增进我们的理解。
Am J Med. 2006 Oct;119(10 Suppl 1):63-72. doi: 10.1016/j.amjmed.2006.08.009.
7
Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.英国基层医疗环境中初诊慢性阻塞性肺疾病患者的呼吸药物治疗使用情况:一项回顾性队列研究
COPD. 2014 Sep;11(5):521-30. doi: 10.3109/15412555.2014.922064. Epub 2014 Jun 19.
8
The reasons for triple therapy in stable COPD patients in Japanese clinical practice.日本临床实践中稳定期慢性阻塞性肺疾病患者三联疗法的原因。
Int J Chron Obstruct Pulmon Dis. 2015 Jun 4;10:1053-9. doi: 10.2147/COPD.S79864. eCollection 2015.
9
Clinical course of chronic obstructive pulmonary disease: review of therapeutic interventions.慢性阻塞性肺疾病的临床病程:治疗干预综述
Am J Med. 2006 Oct;119(10 Suppl 1):46-53. doi: 10.1016/j.amjmed.2006.08.007.
10
Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes.优化慢性阻塞性肺疾病的维持治疗:改善以患者为中心结局的策略
Clin Ther. 2007 Oct;29(10):2121-33. doi: 10.1016/j.clinthera.2007.10.006.

引用本文的文献

1
Optimization of Nebulized Budesonide in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.布地奈德雾化吸入治疗慢性阻塞性肺疾病急性加重的优化。
Int J Chron Obstruct Pulmon Dis. 2020 Feb 26;15:409-415. doi: 10.2147/COPD.S235125. eCollection 2020.
2
Chronic Bronchitis in Chronic Obstructive Pulmonary Disease. Magnifying Why Smoking Cessation Still Matters Most.慢性阻塞性肺疾病中的慢性支气管炎。凸显戒烟为何仍然最为重要。
Ann Am Thorac Soc. 2016 Jul;13(7):999-1000. doi: 10.1513/AnnalsATS.201605-360ED.
3
Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
英国初级医疗中长效支气管扩张剂起始治疗后两年慢性阻塞性肺疾病患者的特征、疾病负担及成本
Respir Res. 2015 Nov 16;16:141. doi: 10.1186/s12931-015-0295-2.
4
Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: a randomized control trial.雾化吸入类固醇与肠胃外给予类固醇治疗慢性阻塞性肺疾病急性加重的两种不同剂量:一项随机对照试验
Med Sci Monit. 2014 Mar 28;20:513-20. doi: 10.12659/MSM.890210.